SUPREME COURT STRIKES DOWN FDA PRE-EMPTION

This convoluted attempt by the FDA to undermine consumer safety was one of the main themes in my 2006 book, Fight for Your Health: Exposing the FDA’s Betrayal of America. The Bush Administration had intentionally appointed anti-safety people in high positions within the FDA, starting with its Chief Counsel, Daniel Troy (and continued as a legal philosophy after Troy was forced out for his Big Pharma connections). Troy set in motion the legal problem the Supreme Court just decided.

During the final years of the Bush administration cancer industry insider Andrew von Eschenbach, MD, was appointed to run the FDA, and Wall Street insider, Scott Gottlieb, MD, was second in command. These individuals sought to fully implement the FDA label as senior to any rights of citizens. Their intention was to make sure that new biotech drugs would be protected from lawsuits, as the FDA wanted to speed new and even more dangerous drugs onto the market so as to foster the development of the biotech industry. In essence, the FDA management wanted to turn the American public into one large clinical experiment, with no right of recourse when injured.

This was occurring against a backdrop wherein the FDA couldn’t even name all the drugs currently on the market, had failed to demand required aftermarket follow up safety testing on drugs, and had intentionally withheld safety information on existing drugs from the public. The current situation with drugs is that almost no drug, even blockbusters and those in use for decades, have an accurate risk/benefit profile.

Americans who use medications are already taking risks of unknown magnitude, which is a main reason over 100,000 Americans are killed every year and over 3 million are injured so seriously they need hospital care (ironically, over half those injuries occur while already in the hospital).

The FDA knows full well that when a drug is approved for the market the full extent of the side effects won’t be known for years. History shows us time and again that Big Pharma actively hides risk data from the FDA and pays for “science” that distorts reality. This irresponsible behavior goes along with closed-door negotiations with the FDA, and has resulted in numerous drug disasters like Vioxx. FDA managers oftentimes go against the wishes of their own safety scientists and then move on to six figure salaries in the industry they regulate. Doctors are not apprised of the actual risks and consumers are in the dark.

Currently, there are 450,000 additional new cases of heart failure every year in Americans over 65, a fact that parallels the increased use of heart-weakening statins in this older group. It is only a matter of time before the shoe drops on the 20-billion-dollar-a-year statin industry.

The FDA insistence that a drug label, based on what is known at the time of approval, should supersede citizen’s states rights to sue if they were injured, has almost nothing to do with consumer safety. Rather, it is a federal power grab that is in the best financial interests of Big Pharma and Big Biotech, industries that do not have consumer safety as their top priority.

By the way, don’t think President Obama is on the side of the citizens. In the health care section of the stimulus bill, there is specific pre-emption language. If the federal government is in charge of health care it will be named in future lawsuits when patients are injured from the care it doles out or doesn’t allow.

The current Supreme Court ruling will undermine any system of federal health care wherein the drugs being used are injuring people. Experts believe this system is so badly broken, due to gross FDA management incompetence, that it will take 10 years of studies and many billions of dollars just to understand the actual risks of the drugs Americans are already taking.

In writing for the majority, Justice John Paul Stevens put Big Pharma on notice. The defendant in this case, Wyeth, had argued that it could not comply with both federal and state law. Stevens told them they had a fundamental misunderstanding of regulation and were trying to hide behind the FDA, going on to say that it is a central premise of federal drug regulation that the manufacturer bears responsibility for the content of its label at all times. That is not the news Big Pharma wanted to hear.

Stevens went on to write that there was no merit in the argument that the FDA’s labeling decisions could supersede state law, saying that this argument was “an untenable interpretation of congressional intent and an overbroad view of an agency’s power to pre-empt state law.” He pointed out that the FDA tried to push this on the public without any opportunity for comment from the public or from states, all done against a backdrop wherein the FDA is not able to keep up with safety issues in the first place, meaning that the FDA position lacked “thoroughness, consistency and persuasiveness.” Stevens stated that under such lacking standards the Bush position “is entitled to no weight.”

This is a major victory for all Americans and for states. While the case itself is on the topic of Big Pharma and the FDA, the ruling is sweeping in nature and will extend far beyond prescription drugs. States have just been handed a major legal ruling against the ever-growing incursion of federal power.